Actively Recruiting
Study of Becotatug Vedotin Plus PD-1 Inhibitor for Locally Recurrent Nasopharyngeal Carcinoma Evaluating Treatment Response and Surgery Outcomes
Led by Hongmeng Yu · Updated on 2026-08-24
25
Participants Needed
1
Research Sites
104 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying patients with locally recurrent nasopharyngeal carcinoma confirmed by tissue tests. The study evaluates the combination of becotatug vedotin with a PD-1 inhibitor to treat this condition. This is a Phase II, exploratory, single-arm trial focused on assessing treatment response and progression-free survival over one and two years. Participants will receive three cycles of becotatug vedotin, given as an intravenous infusion every three weeks, combined with a PD-1 immune checkpoint inhibitor selected by the investigator. After this treatment, imaging and surgical evaluations will determine whether the tumor can be removed by endoscopic nasal surgery. Those eligible for surgery will undergo the procedure followed by a maintenance treatment plan decided by a multidisciplinary team. For patients not suitable for surgery, the team will select maintenance therapy or alternative treatments. During the study, participants will have tumor assessments by CT or MRI before treatment and after cycles to monitor response. Researchers will measure objective response rate at 12 weeks and progression-free survival at one and two years. Additional outcomes include overall survival, recurrence-free survival, and rates of complete pathological response and resection. The study involves careful monitoring of organ function, pregnancy testing, and safety to ensure appropriate treatment and follow-up until study completion in 2029.
CONDITIONS
Brief Title
Becotatug Vedotin Combined With a PD-1 Inhibitor in the Treatment of Locally Advanced Recurrent Nasopharyngeal Carcinoma.
Research Team
L
Li Yan, MD
X
Xiaole Song, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here